<DOC>
	<DOCNO>NCT02981784</DOCNO>
	<brief_summary>Effective treatment option chronic myeloid leukemia ( CML ) Philadelphia-positive ( Ph+ ) acute lymphoblastic leukemia ( ALL ) patient T315I mutation . This study compare overall survival ( OS ) CML Ph+ ALL patient treat ponatinib versus allogeneic stem cell transplantation ( allo-SCT ) .</brief_summary>
	<brief_title>Comparative Evaluation Results Allogeneic Hematopoietic Stem Cells Versus Ponatinib CML Patients Carrying Mutation T315I</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>CML phase T315I mutation Ph+ ALL T315I mutation Being treat PACE trial accord criterion phase II trial Or allogeneic stem cell transplant source allogeneic cell condition regimen . Ph negative patient Patients 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>chronic myeloid leukemia ( CML )</keyword>
	<keyword>Philadelphia-positive ( Ph+ )</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
</DOC>